Explanipedia

Supplementary Material SM1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open

Fabrice Barlési, Stefan Michiels, Judith Raimbourg, Anne Madroszyk, Élisabeth Quoix , et al. · 2025

Supplementary materials - substudy 1 statistical report

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open

Fabrice Barlési, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Catherine Daniel , et al. · 2025

Supplementary Figure 2. Forest plot with subgroup analysis for PFS in substudy 1.

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open

Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel , et al. · 2025

Supplementary Figure 5. Forest plot with subgroup analysis for OS in substudy 2.

Study Protocol from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open

Fabrice Barlési, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Henri Janicot , et al. · 2025

Study protocol

Supplementary Figure Legends SL1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open

Fabrice Barlési, Pascale Tomasini, Stefan Michiels, Judith Raimbourg, Anne Madroszyk , et al. · 2025

Supplementary Figure legends 1-5

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open

Pascale Tomasini, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Clarisse Audigier-Valette , et al. · 2025

Supplementary Figure 3. Forest plot with subgroup analysis for OS in substudy 1.

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open

Fabrice Barlési, Maryam Karimi, Stefan Michiels, Catherine Daniel, Anne Madroszyk , et al. · 2025

Supplementary Figure 4. Forest plot with subgroup analysis for PFS in substudy 2.

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study Open

Jean Mourlanette, G. Rousseau-Bussac, Siham Mallah, Florian Guisier, Gérard Zalcman , et al. · 2025

168P Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial Open

L. Collet, Maude Ardin, D. Venet, Jean‐Philippe Berthet, Sarah Barrin , et al. · 2024

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial Open

Isabelle Ray‐Coquard, Aude-Marie Savoye, Camille Schiffler, Marie‐Ange Mouret‐Reynier, Olfa Derbel , et al. · 2024

Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial Open

Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz , et al. · 2024

For this unselected PM population, efficacy and safety outcomes compared favorably with CheckMate 743 trial results.

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers Open

Marco Tagliamento, Marie Morfouace, Charalambos Loizides, Júlio Oliveira, Laurent Greillier , et al. · 2024

Real-World Efficacy and Safety of Combination Nivolumab Plus Ipilimumab for Untreated, Unresectable, Pleural Mesothelioma: The Meso-Immune (Gfpc 04-2021) Trial Open

Olivier Bylicki, Florian Guisier, Arnaud Scherereel, Catherine Daniel, Aurélie Swalduz , et al. · 2024

782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under ≥2<sup>nd</sup>line anti-PD1/L1 monotherapy in the PIONeeR project Open

Marcellin Landri, Margot Vasseur, Florence Monville, Vanina Leca, Chafik Hamdad , et al. · 2023

Background Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide.¹ Despite the promise shown by immune checkpoint inhibitors (ICIs) in enhancing survival and tumor control for a subset o…

2179P Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study Open

E. Sebbag, Nicolas Cloarec, I. Monnet, A. Najem, S.L. Rajpar , et al. · 2023

2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort Open

Marie Morfouace, Daniel Schulz, Nils Eling, Flavia Marzetta, C. Loizides , et al. · 2023

Data from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial Open